- Home
- MNOV vs YI Comparison
MNOV vs YI Comparison
Compare MNOV & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- YI
- Stock Information
- Founded
- MNOV 2000
- YI 2010
- Country
- MNOV United States
- YI China
- Employees
- MNOV N/A
- YI N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- MNOV Health Care
- YI Consumer Staples
- Exchange
- MNOV Nasdaq
- YI Nasdaq
- Market Cap
- MNOV 76.0M
- YI 69.4M
- IPO Year
- MNOV 2005
- YI N/A
- Fundamental
- Price
- MNOV $1.41
- YI $8.47
- Analyst Decision
- MNOV Strong Buy
- YI
- Analyst Count
- MNOV 1
- YI 0
- Target Price
- MNOV $9.00
- YI N/A
- AVG Volume (30 Days)
- MNOV 13.2K
- YI 32.0K
- Earning Date
- MNOV 05-08-2025
- YI 03-20-2025
- Dividend Yield
- MNOV N/A
- YI N/A
- EPS Growth
- MNOV N/A
- YI N/A
- EPS
- MNOV N/A
- YI N/A
- Revenue
- MNOV N/A
- YI $1,973,017,082.00
- Revenue This Year
- MNOV N/A
- YI N/A
- Revenue Next Year
- MNOV N/A
- YI N/A
- P/E Ratio
- MNOV N/A
- YI N/A
- Revenue Growth
- MNOV N/A
- YI N/A
- 52 Week Low
- MNOV $1.12
- YI $0.41
- 52 Week High
- MNOV $2.55
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- MNOV 33.27
- YI 47.55
- Support Level
- MNOV $1.44
- YI $8.01
- Resistance Level
- MNOV $1.53
- YI $10.52
- Average True Range (ATR)
- MNOV 0.05
- YI 0.85
- MACD
- MNOV 0.01
- YI -0.30
- Stochastic Oscillator
- MNOV 0.00
- YI 14.03
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.